Other
Jun 2024BioPharmGuy labels Synkrino Biotherapeutics defunct based on California filings in this period, but this conflicts with other public sources that still show the company as active.
SourceSynkrino's AI, SATIS is a powerful, unbiased discovery system for…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Synkrino Biotherapeutics is a YC S18 AI-powered biotech/drug-discovery company built around SATIS, an AI + immunology discovery engine that analyzes patient immune/RNA-seq data to identify disease mechanisms and novel therapeutic targets. Public sources conflict on headquarters and lifecycle status: the company site/YC-style directories point to Berkeley/Oakland, while some third-party directories later label it defunct.
Primary product
SATIS (AI + Immunology Discovery Engine) for drug-target discovery from patient immune data
Founded
2018
Headquarters
Berkeley, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI drug discovery / therapeutic discovery and development
Offices
Open Positions
0 jobs at Synkrino Biotherapeutics
No open positions
Check back later for new openings